Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

"We are eager to expand our understanding of the benefits of spinal cord epidural stimulation in our endeavor to make this technology more accessible to all with spinal cord injury," Angeli said.

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...